Haddad E, Landais P, Friedrich W, Gerritsen B, Cavazzana-Calvo M, Morgan G, Bertrand Y, Fasth A, Porta F, Cant A, Espanol T, Müller S, Veys P, Vossen J, Fischer A
Unité d'Immunologie et d'Hématologie Pédiatriques, Département de Pédiatrie, Hôpital Necker-Enfants Malades, Paris, France.
Blood. 1998 May 15;91(10):3646-53.
We have performed a retrospective analysis of the development of T- and B-cell functions after HLA-nonidentical T-cell-depleted bone marrow transplantation (BMT) performed in 193 patients with severe combined immunodeficiency (SCID) at 18 European centers between December 1982 and December 31, 1993. One hundred sixteen of 193 patients were alive with evidence of engraftment 6 months after BMT. Development of T-cell function occurred earlier than B-cell function and was achieved more frequently up to the time of last follow-up. The median time to achieve normal T-cell function was 8.7 months, whereas the median time to achieve normal B-cell function was 14.9 months. Twenty-four patients died later than 6 months post-BMT, mainly due to chronic graft-versus-host disease (cGVHD) and/or viral infection. Absence of T-cell reconstitution 6 months after BMT, unlike absence of B-cell reconstitution, was associated with a poor outcome. Two additional factors were associated with a poor outcome: presence of cGVHD 6 months after BMT and B- SCID versus B+ SCID. However, two of these three factors remained as significant prognostic factors in a multivariate analysis: the absence of T-cell function and the presence of cGVHD 6 months after BMT. Analysis of the factors influencing the development of immune reconstitution showed that T- and B-cell functions occurred earlier and more frequently in B+ SCID versus B- SCID patients. Acute GVHD was associated with a slower development of T-cell function at 6 months, and cGVHD had a negative influence on the development of T-cell function afterwards, but neither acute nor chronic GVHD was found to influence the development of B-cell function. Once engraftment occurred, whether patients had or had not received Busulfan in the conditioning regimen did not influence the kinetics and quality of T-cell function development. In a multivariate study, two factors were found to influence the T-cell function 6 months after BMT: type of SCID and acute GVHD. The results of this retrospective analysis should lead to new protocols adapted to SCID disease, considering that disease-related as well as BMT-related parameters influence the development of immune function and thereby long-term outcome after HLA-nonidentical T-cell-depleted BMT.
我们对1982年12月至1993年12月31日期间在18个欧洲中心为193例重症联合免疫缺陷(SCID)患者进行的HLA不相合且去除T细胞的骨髓移植(BMT)后T细胞和B细胞功能的发展进行了回顾性分析。193例患者中有116例在BMT后6个月存活且有植入证据。T细胞功能的发展早于B细胞功能,并且在最后一次随访时更频繁地实现。达到正常T细胞功能的中位时间为8.7个月,而达到正常B细胞功能的中位时间为14.9个月。24例患者在BMT后6个月后死亡,主要原因是慢性移植物抗宿主病(cGVHD)和/或病毒感染。与B细胞重建缺失不同,BMT后6个月T细胞重建缺失与不良预后相关。另外两个因素与不良预后相关:BMT后6个月存在cGVHD以及B - SCID与B + SCID。然而,在多变量分析中,这三个因素中的两个仍然是显著的预后因素:T细胞功能缺失和BMT后6个月存在cGVHD。对影响免疫重建发展的因素分析表明,与B - SCID患者相比,B + SCID患者的T细胞和B细胞功能出现得更早且更频繁。急性GVHD与6个月时T细胞功能发展较慢相关,cGVHD随后对T细胞功能发展有负面影响,但未发现急性或慢性GVHD影响B细胞功能的发展。一旦发生植入,无论患者在预处理方案中是否接受过白消安,均不影响T细胞功能发展的动力学和质量。在一项多变量研究中,发现两个因素影响BMT后6个月的T细胞功能:SCID类型和急性GVHD。考虑到与疾病相关以及与BMT相关的参数会影响免疫功能的发展,从而影响HLA不相合且去除T细胞的BMT后的长期结果,这项回顾性分析的结果应能促成适应SCID疾病的新方案。